Monday, March 20, 2023 11:44:42 AM
Recent ALVO News
- Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 • GlobeNewswire Inc. • 05/02/2024 11:15:00 AM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • Business Wire • 04/30/2024 08:00:00 AM
- U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) • GlobeNewswire Inc. • 04/30/2024 08:00:00 AM
- Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) • GlobeNewswire Inc. • 04/24/2024 08:00:00 AM
- Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) • GlobeNewswire Inc. • 04/19/2024 10:10:00 AM
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) • Business Wire • 04/16/2024 09:43:00 PM
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) • GlobeNewswire Inc. • 04/16/2024 09:30:00 PM
- Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 • GlobeNewswire Inc. • 04/03/2024 11:41:03 AM
- Alvotech Announces Increase in Number of Own Shares • GlobeNewswire Inc. • 03/22/2024 08:15:00 PM
- Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update • GlobeNewswire Inc. • 03/20/2024 08:15:00 PM
- U.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices Dip • IH Market News • 03/20/2024 11:17:32 AM
- Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET • GlobeNewswire Inc. • 03/05/2024 09:00:00 PM
- Alvotech Appoints Interim Chief Quality Officer • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share • GlobeNewswire Inc. • 02/26/2024 09:25:00 AM
- Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® • GlobeNewswire Inc. • 02/24/2024 01:15:09 AM
- Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® • Business Wire • 02/24/2024 01:15:00 AM
- Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) • GlobeNewswire Inc. • 02/15/2024 11:30:00 AM
- Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® • GlobeNewswire Inc. • 01/29/2024 09:00:00 AM
- Alvotech Shares Climb After FDA Concludes Facility Inspection • Dow Jones News • 01/19/2024 05:31:00 PM
- Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 • GlobeNewswire Inc. • 01/19/2024 04:30:00 PM
- STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara • GlobeNewswire Inc. • 01/10/2024 08:30:00 AM
- Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) • GlobeNewswire Inc. • 01/03/2024 08:30:00 AM
- Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® • GlobeNewswire Inc. • 11/29/2023 09:00:00 AM
- Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update • GlobeNewswire Inc. • 11/28/2023 09:15:00 PM
- Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET • GlobeNewswire Inc. • 11/21/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM